Identification of CD19 and CD20 peptides for induction of antigen-specific CTLs against B-cell malignancies

Clinical Cancer Research

Volumn 11, Issue 4, 2005, Pages 1629-1638

  Bae, Jooeun ^a,b   Martinson, Jeffrey A ^a   Klingemann, Hans G ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN; CD20 ANTIGEN; CD28 ANTIGEN; CD3 ANTIGEN; CD45RA ANTIGEN; CD45RO ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYCLIC GMP; GAMMA INTERFERON; HLA A2 ANTIGEN; LYSYLLEUCYLMETHIONYLSERYLPROLYLLYSYLLEUCYLTYROSYLVALINE; PEPTIDE DERIVATIVE; RECOMBINANT INTERLEUKIN 2; SERYLLEUCYLPHENYLALANYLLEUCYLGLYCYLISOLEUCYLLEUCYLSERYLVALINE; UNCLASSIFIED DRUG;

ANTIGEN SPECIFICITY; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; BURKITT LYMPHOMA; CELL PROLIFERATION; CHRONIC LEUKEMIA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DRUG IDENTIFICATION; DRUG TARGETING; HUMAN; HUMAN CELL; IMMUNOGENICITY; IMMUNOTHERAPY; INTERFERON PRODUCTION; MEMORY CELL; MULTIPLE MYELOMA; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

AMINO ACID SEQUENCE; ANTIGENS, CD19; ANTIGENS, CD20; B-LYMPHOCYTES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL PROLIFERATION; CYTOTOXICITY, IMMUNOLOGIC; HLA-A2 ANTIGEN; HUMANS; INTERFERON TYPE II; K562 CELLS; OLIGOPEPTIDES; RECEPTORS, COMPLEMENT 3D; T-LYMPHOCYTES, CYTOTOXIC;

EID: 14644417182     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1612     Document Type: Article

References (61)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin 2001;51:15-36.
2. Alexanian R, Dimopoulos M. The treatment of multiple myeloma. N Engl J Med 1994;330:484-9.
3. Barlogie B. Plasma cell myeloma. In: Beutler E, Lichtman mol/L, Coller B, Kipps T, editors. William's hematology. 5th ed. New York (NY): McGraw-Hill; 1995. p. 1109-26.
4. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-7.
5. Tricot G, Jagannath S, Vesole DH, Crowley J, Barlogie B. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995;16:7-11.
6. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991;9:271-96.
7. Wen YJ, Min R, Tricot G, Barlogie B, Yi Q. Tumor lysate-specific cytotoxic T lymphocytes in multiple myeloma: promising effector cells for immunotherapy. Blood 2002;99:3280-5.
8. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996;2:52-8.
9. Reichardt VL, Okada CY, Liso A, et al. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-feasibility study. Blood 1999;93: 2411-9.
10. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol 1997;15: 433-44.
11. Riddell SR, Murata M, Bryant S, Warren EH. T-cell therapy of leukemia. Cancer Control 2002;9:114-22.
12. Papadopoulos EB, Ladanyi M, Emanuel D, et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994;330:1185-91.
13. Savoldo B, Heslop HE, Rooney CM. The use of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus induced lymphoma in transplant recipients. Leuk Lymphoma 2000;39:455-64.
14. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F, Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2000; 75:235-82.
15. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995;18: 385-97.
16. Uckun FM, Jaszcz W, Ambrus JL, et al. Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins. Blood 1988;71:13-29.
17. Stamenkovic I, Seed B. CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. J Exp Med 1988; 168: 1205-10.
18. Ryan DH, Nuccie BL, Ritterman I, Liesveld JL, Abboud CN, Insel RA. Expression of interleukin-7 receptor by lineage-negative human bone marrow progenitors with enhanced lymphoid proliferative potential and B-lineage differentiation capacity. Blood 1997;89: 929-40.
19. Tedder TF, Isaacs CM. Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes: a new member of the immunoglobulin superfamily. J Immunol 1989;143:712-7.
20. Nadler LM, Anderson KC, Marti G, et al. B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol 1983;131:244-50.
21. Uckun FM. Regulation of human B-cell ontogeny. Blood 1990;76: 1908-23.
22. Nicholson IC, Lenton KA, Little DJ, et al. Construction and characterization of a functional CD19 specific single chain Fv fragment for immunotherapy of B lineage leukemia and lymphoma. Mol Immunol 1997;34:1157-65.
23. Kabat EA, Wu TT, Perry HM, Gottesman KS, Foeller C. Sequences of proteins of immunological interest. 5th ed. Bethesda (MD): US Department of Health and Human Services; 1991. p. 91-3242 [NIH publication].
24. Davis TA, Czerwinski DK, Levy R. Therapy of B-cell lymphoma with anti-CD20 antibodies can result in the loss of CD20 antigen expression. Clin Cancer Res 1999;5:611-5.
25. Tedder TF, Engel P. CD20: a regulator of cell-cycle progression of B lymphocytes. Immunol Today 1994;15:450-4.
26. Tedder TF, Streuli M, Schlossman SF, Saito H. Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B-lymphocytes. Proc Natl Acad Sci U S A 1988;85:208-12.
27. Hooijberg E, Sein JJ, van den Berk PC, et al. Eradication of large human B cell tumors in nude mice with unconjugated CD20 monoclonal antibodies and interleukin 2. Cancer Res 1995;55:2627-34.
28. Press OW, Howell-Clark J, Anderson S, Bernstein I. Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 1994;83:1390-7.
29. Press OW, Farr AG, Borroz KI, Anderson SK, Martin PJ. Endocytosis and degradation of monoclonal antibodies targeting human B-cell malignancies. Cancer Res 1989;49:4906-12.
30. McLaughlin P, Grillo-Lopez A, Maloney D. Efficacy controls in long-term follow-up of patients treated with rituximab for relapsed or refractory, low-grade or follicular NHL. Blood 1998;92:414-5A.
31. Zweerink HJ, Gammon MC, Utz U, et al. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J Immunol 1993;150:1763-71.
32. Amrolia PJ, Reid SD, Gao L, et al. Alloreactive cytotoxic T cells specific for human CD45 show potent antileukemic activity. Blood 2003; 101:1007-14.
33. Pangalis GA, Dimopoulou MN, Angelopoulou MK, et al. Campath-1H (anti-CD52) monoclonal antibody therapy in lymphoproliferative disorders. Med Oncol 2001;18:99-107.
34. Hale G, Zhang MJ, Bunjes D, et al. Improving the outcome of bone marrow transplantation by using CD52 monoclonal antibodies to prevent graft-versus-host disease and graft rejection. Blood 1998;92:4581-90.
35. Azuma K, Shichijo S, Maeda Y, et al. Mutated p53 gene encodes a nonmutated epitope recognized by HLA-B*4601-restricted and tumor cell-reactive CTLs at tumor site. Cancer Res 2003;63:854-8.
36. Chada S, Mhashilkar A, Roth JA, Gabriolvich D. Development of vaccines against self-antigens: the p53 paradigm. Curr Opin Drug Discov Devel 2003;6:169-73.
37. Zwaveling S, Van der Burg SH, Menon AG, Melief CJ, Offringa R. Immunotherapy of cancer through targeting of the p53 tumor antigen. Arch Immunol Ther Exp (Warsz) 2002;50:297-305.
38. Knutson KL, Disis ML. Clonal diversity of the T-cell population responding to dominant HLA-A2 epitope of HER-2/neu after active immunization in an ovarian cancer patient. Hum Immunol 2002;63: 547-57.
39. Scardino A, Gross DA, Alves P, Schultze JL, Graff-Dubois S, Faure O. HER-2/neu and hTERT cryptic epitopes as novel targets for broad spectrum tumor immunotherapy. J Immunol 2002;168:5900-6.
40. Tanaka H, Tsunoda T, Nukaya I, et al. Mapping the HLA-A24-restricted T-cell epitope peptide from a tumor-associated antigen HER2/neu: possible immunotherapy for colorectal carcinomas. Br J Cancer 2001;84:94-9.
41. Bae J, Martinson JA, Klingemann HG. Identification of novel CD33 antigen-specific peptides for the generation of cytotoxic T lymphocytes against acute myeloid leukemia. Cell Immunol 2004;227:38-50.
42. Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma 1995;18: 385-97.
43. Roberts WK, Livingston PO, Agus DB, Pinilla-Ibarz J, Zelenetz A, Scheinberg DA. Vaccination with CD20 peptides induces a biologically active, specific immune response in mice. Blood 2002;99:3748-55.
44. Lauritzsen GF, Weiss S, Bogen B. Anti-tumour activity of idiotype-specific, MHC-restricted Th1 and Th2 clones in vitro and in vivo. Scand J Immunol 1993;37:77-85.
45. Dabadghao S, Bergenbrant S, Anton D, He W, Holm G, Yi Q. Anti-idiotypic T-cell activation in multiple myeloma induced by M-component fragments presented by dendritic cells. Br J Haematol 1998; 100:647-54.
46. Yi Q, Dabadghao S, Osterborg A, Bergenbrant S, Holm G. Myeloma bone marrow plasma cells: evidence for their capacity as antigen-presenting cells. Blood 1997;90:1960-7.
47. Knutson KL, Schiffman K, Cheever MA, Disis ML. Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369-377, results in short-lived peptide-specific immunity. Clin Cancer Res 2002; 8:1014-8.
48. + lymphocytes share the same effector-memory phenotype but exhibit functional differences in acute hepatitis B and C. J Virol 2002;76: 12423-34.
49. Jager E, Hohn H, Necker A, et al. Peptide-specific CD8+ T-cell evolution in vivo: response to peptide vaccination with Melan-A/MART-1. Int J Cancer 2002;98:376-88.
50. + T cells in xenografted nude mice. J Immunol 2003;170:1183-90.
51. Slingluff CL Jr, Petroni GR, Yamshchikov GV, et al. Clinical and immunologic results of a randomized phase II trial of vaccination using four melanoma peptides either administered in granulocyte-macrophage colony-stimulating factor in adjuvant or pulsed on dendritic cells. J Clin Oncol 2003;21:4016-26.
52. Jager E, Jager D, Knuth A. Antigen-specific immunotherapy and cancer vaccines. Int J Cancer 2003;106:817-20.
53. Heslop HE, Stevenson FK, Molldrem JJ. Immunotherapy of hematologic malignancy. Hematology (Am Soc Hematol Educ Program) 2003;331-49.
54. Tanaka S, Harada M, Mine T, et al. Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery. J Immunother 2003;26:357-66.
55. Lieberman J, Skolnik PR, Parkerson GR III, et al. Safety of autologous, ex vivo-expanded human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte infusion in HIV-infected patients. Blood 1997;90:2196-206.
56. Rooney CM, Roskrow MA, Suzuki N, Ng CY, Brenner MK, Heslop H. Treatment of relapsed Hodgkin's disease using EBV-specific cytotoxic T cells. Ann Oncol 1998;9 Suppl 5:S129-32.
57. Marktel S, Magnani Z, Ciceri F, et al. Immunologic potential of donor lymphocytes expressing a suicide gene for early immune reconstitution after hematopoietic T-cell-depleted stem cell transplantation. Blood 2003;101:1290-8.
58. Kramm CM. Alternative concepts of suicide gene therapy for graft-versus-host disease after adoptive immunotherapy. Acta Haematol 2003; 110:132-8.
59. Burger SR, Kadidlo DM, Basso L, Bostrom N, Orchard PJ. Cellular engineering of HSV-tk transduced, expanded T lymphocytes for graft-versus-host disease management. Acta Haematol 2003;110: 121-31.
60. Igarashi T, Ohtsu T, Fujii H, et al. Re-treatment of relapsed indolent B-cell lymphoma with rituximab. Int J Hematol 2001;73:213-21.
61. Maloney DG. Preclinical and phase I and II trials of rituximab. Semin Oncol 1999;26:74-8.